Main | VISTA Clinical Trials

1-855-VIEWVISTA (1-855-843-9847)

LIGHT SCREEN
DARK SCREEN
ENLARGE TEXT

DIAGNOSED WITH X-LINKED RETINITIS PIGMENTOSA?

You or your child may qualify to participate in the VISTA clinical trial, a phase 2/3 study evaluating an investigational gene therapy for the treatment of Retinitis Pigmentosa.

TRAVEL FOR STUDY-RELATED ASSESSMENTS WILL BE PROVIDED FOR ELIGIBLE STUDY PARTICIPANTS AND THEIR CAREGIVER.

ABOUT THE VISTA CLINICAL TRIAL

The VISTA clinical trial is studying an investigational (not yet FDA-approved) gene therapy called AGTC-501 for patients with X-linked retinitis pigmentosa (XLRP).
Gene therapy is the process of injecting a healthy gene to replace a damaged or mutated one.
The investigational gene therapy (AGTC-501) is designed to replace the mutated RPGR gene that causes XLRP.
The purpose of the VISTA phase 2/3 clinical trial is to evaluate the safety and effectiveness of AGTC-501 and to determine whether it may help a person with XLRP see better or maintain their current vision.

You or Your Child May Be Eligible for the VISTA Clinical Trial If:

Diagnosed with XLRP
and have RPGR gene mutation (confirmed by genetic testing)

Best Corrected Visual Acuity in at least one eye is between 20/32 and 20/200

Male

Between 13 and 50
years of age

Couple sitting on beach with dog.

VISTA Clinical Trial Participation

Clinical research studies help scientists and doctors explore whether a medical therapy is safe and effective in humans. The data gathered from clinical research helps the development of medical therapies, which may improve how patients receive medical care and the way they are treated for their conditions.

There is no guarantee that this investigational gene therapy will improve your or your child’s XLRP symptoms, but what researchers learn may lead to better medications and treatments for patients with XLRP in the future.

DO YOU/YOUR CHILD QUALIFY?
REFER A PATIENT

FOR HEALTHCARE PROFESSIONALS

Click here for more information about the VISTA clinical trial.

Think you have a patient that might qualify for the VISTA clinical trial?

Refer a specialist that treats patients with RP or XLRP.

Healthcare Providers - Click Here to Refer a Patient